In the tumor microenvironment, HVEM is often expressed on cancer cells, enabling them to suppress BTLA+ immune cells via direct contact, thereby promoting immune evasion and correlating with adverse clinical outcomes [39]. This evidence concerns the gene BTLA and neoplasm.